EXCLUSIVE: Humacyte, Alpha Healthcare CEOs Talk SPAC Deal, Technology, Trials On 'SPACs Attack'
Humacyte is set to go public via the special purpose acquisition company Alpha Healthcare Acquisition Corp (NASDAQ: AHAC) in a deal that values the company at around $800 million.
